big pharma - the way forward anders ekblom executive vice president global drug development...
Post on 19-Dec-2015
217 views
TRANSCRIPT
Big Pharma - The Way Forward
Anders Ekblom Executive Vice PresidentGlobal Drug Development
Swedish-American Life Science Summit20th August 2009
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
AstraZenecaGlobal R&D organisation
MontrealBoston
WilmingtonGaithersburg
Bangalore
Osaka
Reims
SödertäljeMölndalLund
Alderley ParkCharnwoodCambridge
Shanghai
Mountain View
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
Agenda
The Pharmaceutical Industry in Perspective
Challenges
Opportunities
Scorecard for Future Success – AZ Case Study
The Pharmaceutical Industryin Perspective
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
Presentation prepared for AstraZeneca: 14th May 2009
0
100
200
300
400
500
600
700
800
2002 2003 2004 2005 2006 2007 2008
VA
LUE
SA
LES
US
$ B
N
-5%
0%
5%
10%
15%
20%
25%
VA
LUE
GR
OW
TH
% (
US
$)
Global USA EU5J apan Pharmerging
Source: IMS Health MIDAS MAT December 2008, Pharmerging markets = China, India, Russia, Brazil, Mexico, Turkey and South Korea.
Global Sales and Market Growth Pharmaco challenges
Global Pharma Historical Market Dynamics & Current Economic Environment
> The USA/top 5 Europe/Japan no longer ‘Mr Atlas’
> Lower GDP growth and tax revenues will impact healthcare budgets/promote more aggressive cost containment
> Biotechnology, a big growth area, affected by lack of investment funds
> Several big selling drugs will face patent expires during the next few years
> The most attractive areas for growth are in emerging markets
Pharmaceutical Industry -Global sales
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
> $897+ million USD to bring one drug from concept to market
> 12 years to develop a new medicine
> One in 5000 new chemical compounds make it to market
> 80% drugs fail leaving 20% to fund the R&D engine
Pharmaceutical Industry -Key facts
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
0
10
20
30
40
50
60
USA Europe Japan Rest Of World
% o
f tot
al R
&D
exp
endi
ture
This graph is based on data from 22 companies (10 Major and 12 Mid and Other)
Major companies are defined as those spending ≥US$ 1.8 billion in 2005 on ethical pharmaceutical R&D.Mid and Other companies are defined as those spending <US$ 1.8 billion in 2005 on ethical pharmaceutical R&D.
Pharmaceutical Industry -R&D expenditure
Pharmaceutical IndustryChallenges
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
Industry Overview: Global R&D expenditure, development times, global sales and NME output 1998 - 2008
0
50
100
150
200
250
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008*Ind
ex
ed
to 1
99
8
R&D expenditure Development times NME output Sales
*The development time data point for 2008 includes data from 2007 and 2008 only
Source: CMR International (2009 FactBook) & IMS Health
+160% Sales
+ 80% R&D
+30% Dev.times
-43% NMEs
Challenges -Industry Trends
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
Black numerals refer to number of NME entries required in each phase to obtain 1 Approval; figures in red box are success rates for each phase
Source: PBF R&D General Metrics 2008, slide 198Cohort: PBF member companies
NME Success Rates By Phase And Overall2004-2008 Industry Portrait, Pure
Challenges -R&D Productivity
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
> Mergers (risk vs. reward)
> 75% of large mergers fail to create shareholder value greater than industry averages
> Pricing Pressures (ROI on R&D)
> NICE and HTA
> Patent Expiry
> 20 year patent – 12 year development time = limited time to recoup R&D costs
Challenges -Industry Trends continued
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
NICE: Impact so far
Approved
Restricted
Research only
No use
Result of 232 reviews and decisions
Pharmaceutical IndustryOpportunities
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
Opportunities -Future Unmet Medical Need
> Symptomatic Disease modification/prevention
> One size fits all Personalised medicine
> Ageing population
> Rational sequence of treatment and combinations
ObesityLiving longer
Stress/PainAllergy
Smoking addiction
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
We apply our extensive scientific expertise in this field to
> drive greater disease understanding
> ensure the safety of medicines
> improve efficacy & success rate
Model MarkerMechanism
Patients
Opportunities -Predictive Science
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
Examples of Predictive Science
> Identifying and using biomarkers to measure disease progress or the effects of a drug or combination of drugs in treatment.
> Using sophisticated computational and imaging technologies to model what happens in biological systems, which can help us predict safety, efficacy and doses before moving our studies into man.
> Looking for a better model for animal-to-man predictions through translational understanding of PK/PD relationships.
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
> Emerging areas of research that promise to transform our understanding of human health and disease in the coming years
> Biologics are increasing due to genomics
> Researchers are discovering how to use human molecules—genes, proteins, and antibodies as drugs
> Fewer toxicological issues with biologics
Opportunities -Biologics & Genetics
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
“ Emerging markets will play a major
part in the future of the (life
science) industries. Companies will
have to significantly expand
investment in emerging markets
across a wide range of activities,
including Research and Development.
“
- Economist Intelligence Unit
& Deloitte Touche Tohmatsu
Opportunities -Emerging Markets
Scorecard for Future SuccessAZ case study
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
“MAKING
THE MOST MEANINGFUL DIFFERENCE
TO PATIENT HEALTH THROUGH GREAT MEDICINES”
Performance PeoplePatient NeedsProducts
Strengthen
the pipeline
Grow the business
Reshape
the business
Change our behaviour and our
culture
Customer-centric
mindset
Lean and agile
organisation
Responsible leaders who make every interaction count
Valued
medicines
The Fast Forward planAstraZeneca - Our Strategy
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
> Cardiovascular and Gastrointestinal
> Oncology and Infection
> Neuroscience
> Respiratory and Inflammation
> New Opportunities
> Across Biologicals, Small Molecules, Vaccines
AstraZenecaAreas of Medical Focus
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
AstraZenecaInnovation Center China (ICC)
>AZ’s newest global R&D centre site
>Focus on translational science by developing knowledge on potential ethnic difference and regional unmet medical needs
>Provide science support for our activities in this region
>Tap into the large talent pool and increasing innovation
ICC facility opening ceremony, Oct 15, 2008
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
AstraZenecaPersonalised Healthcare (PHC)
> AZ evaluates every new drug candidate for PHC opportunity as a core component of the R&D Operating Model
> Key AZ projects in regulatory development actively testing PHC strategies
> IRESSA – PHC in action
> Dedicated team within R&D
“PHC aims to create superior patient outcomes through the use of
healthcare tools and diagnostics, achieving “right treatment, right
patient, right dose, right (first) time”
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
AstraZenecaLCM Update - Iressa
M+, mutation positive; M-, mutation negativePre-planned analysis of patients in which EGFR mutation status was available
Treatment by subgroup
interaction test, p<0.0001
EU approval received across all lines of therapy for EGFR mutation positive NSCLC based on INTEREST, IPASS & full data review – July 09
Probabilityof PFS
In EGFR mutation-positive patients, IRESSA reduces the risk of
progression by 52% vs. doublet chemotherapy
0 4 8 12 16 20 24
Time from randomisation (months)
0.0
0.2
0.4
0.6
0.8
1.0
0 4 8 12 16 20 24
Time from randomisation (months)
0.0
0.2
0.4
0.6
0.8
1.0
Gefitinib EGFR M+ (n=132)Gefitinib EGFR M- (n=91)Carboplatin / paclitaxel EGFR M+ (n=129)
Carboplatin / paclitaxel EGFR M- (n=85)
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
AstraZenecaInnovative Partnerships
> In-licensing• DSP, Dynavax, Argenta
> Acquisitions• Arrow, Kudos, MedImmune
> Spin Outs• Albireo
> Fostering• Cancer Research UK
> Research and Screening• Alcon
> Risk-Sharing• BMS
> Combination Therapy• Pozen, Abbott, Merck
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
AZD6244
MK-2206
First combination of two unapproved agents in early development, from separate pharma companies to treat patients with cancer
Combination will block signalling in the two key pathways involved in cancer cell survival and growth
Combination has much higher chance of providing benefit to patients with cancer than either agent alone
AstraZeneca & Merck Phase 1 Collaboration
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
AstraZenecaBPO in Clinical Data Management (CDM)
> December 2007: AZ partnered with Cognizant for CDM operations
> Largest outsourcing agreement of it’s kind in the pharmaceutical industry
> Drivers:
> Process simplification and efficiencies
> Reduce costs
> Strategic decision to invest in core capabilities
> Benefits:
> $150Mn cost reduction over 5 years
> Standardised high quality delivery process and tools
> $10Mn joint investment to fund continuing transformation and innovation
> Transition successfully delivered in 6 months
> In ‘business as usual’ the CDM engagement is delivering to targets and meeting the broader organization goals of AstraZeneca
Big
Ph
arm
a: T
he W
ay F
orw
ard
And
ers
Ekb
lom
, Exe
cutiv
e V
P D
rug
Dev
elop
men
t
AstraZenecaCase study
Scorecard for Long-Term SuccessSuccess Factor YES NOSmall molecules
Biologicals
Vaccines
Focus on speed, quality and cost
Production & distribution capability
Global reach
Leverage emerging markets
Personalised Healthcare
Innovative Partnerships